Diagnosis and monitoring of CBFB-MYH11-positive acute myeloid leukemia by qualitative and quantitative RT-PCR.
During the last decade, many mutations present in myeloid leukemias have been molecularly characterized. Several of these mutations have clear prognostic impact. The molecular screening of these mutations has now become an essential part in several risk-adapted international clinical trials. Here we describe protocols for the qualitative and quantitative detection of leukemic cells that are characterized by a CBFB-MYH11 gene fusion.